Evidence map›Paper›PMID 41692975›Full record

ArticleBioinformatics (Oxford, England)2026

IgPose: a generative data-augmented pipeline for robust immunoglobulin-antigen binding prediction.

Tien-Cuong Bui, Injae Chung, Wonjun Lee, Junsu Ko, Juyong Lee

Abstract read
In one paragraph

Article in Bioinformatics (Oxford, England), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Tien-Cuong BuiR&D Department, Arontier Co., Ltd., Seoul, 06735, Republic of Korea.
Injae ChungR&D Department, Arontier Co., Ltd., Seoul, 06735, Republic of Korea.ORCID 0000-0002-2902-4677
Wonjun LeeR&D Department, Arontier Co., Ltd., Seoul, 06735, Republic of Korea.
Junsu KoR&D Department, Arontier Co., Ltd., Seoul, 06735, Republic of Korea.ORCID 0000-0001-7416-4591
Juyong LeeR&D Department, Arontier Co., Ltd., Seoul, 06735, Republic of Korea.ORCID 0000-0003-1174-4358

Funding

Bio & Medical Technology Development Program of the National Research FoundationKorean governmentSeoul National University
6 · The paper itself

Abstract

motivationPredicting immunoglobulin-antigen (Ig-Ag) binding remains a significant challenge due to the paucity of experimentally resolved complexes and the limited accuracy of de novo Ig structure prediction.

resultsWe introduce IgPose, a generalizable framework for Ig-Ag pose identification and scoring, built on a generative data-augmentation pipeline. To mitigate data scarcity, we constructed the Structural Immunoglobulin Decoy Database (SIDD), a comprehensive repository of high-fidelity synthetic decoys. IgPose integrates equivariant graph neural networks, ESM-2 embeddings, and gated recurrent units to synergistically capture both geometric and evolutionary features. We implemented interface-focused k-hop sampling with biologically guided pooling to enhance generalization across diverse interfaces. The framework comprises two sub-networks-IgPoseClassifier for binding pose discrimination and IgPoseScore for DockQ score estimation-and achieves robust performance on curated internal test sets and the CASP-16 benchmark compared to physics and deep learning baselines. IgPose serves as a versatile computational tool for high-throughput antibody discovery pipelines by providing accurate pose filtering and ranking. AVAILABILITY AND IMPLEMENTATION: IgPose is available on GitHub (https://github.com/arontier/igpose).

Indexed as

AntigensComputational BiologyImmunoglobulinsSoftwareDatabases, ProteinGraph Neural NetworksImmunoinformaticsProtein BindingAntigensImmunoglobulins

Identifiers

PMID41692975
PMCPMC12989135

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.